×
ON Oncology
Clinically Useful Treatment Algorithms in Benign Hematology Jennifer R. Green, MD Edit rating Mar 21, 2021
0.00 CREDITS
28:25

If you plan to claim credit for this course, you are encouraged to pause the lecture now and take the Pretest (after reviewing Objectives and Disclosures). This will provide a more accurate assessment of your baseline level of knowledge on this topic.

logo play
Limited Access

Audio
Digest
Sample

Explore Purchase Options
 

RECOMMENDED FOR YOU:

Autoplay

Interested in buying this lecture individually?

EM
Clinically Useful Treatment Algorithms in Benign Hematology Oncology | Jennifer R. Green, MD | 0.00 Credits
28:25 | 2021-03-21 | ON120601
×
We are sorry, but your current membership has no access to this lecture.

We suggest you to purchase a Platinum Membership.

×

Educational Objectives

The goal of this program is to improve use of treatment algorithms in patients with bleeding. After hearing and assimilating this program, the clinician will be better able to:

1. Identify the patient at risk for bleeding.

2. Optimize use of inferior vena cava filters in patients who cannot be anticoagulated.

3. Minimize risk when treating patients using direct oral anticoagulants.

Disclosures

Dr. Green receives grant/research support from Baxter international. The planning committee reported nothing to disclose.

Acknowledgements

Dr. Green was recorded at the Scripps Cancer Center’s 40th Annual Conference: Hematology and Oncology 2020, presented by Scripps Health, in San Diego, CA, and held February 15, 2020. For more information on upcoming CME meetings presented by Scripps Health, please visit scripps.org. Audio Digest thanks the speakers and Scripps Health for their cooperation in the production of this program.

CME/CE INFO

Accreditation

The Lippincott Continuing Medical Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Lippincott Continuing Medical Education Institute designates this enduring material for a maximum of 0.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0 MOC points [and patient safety MOC credit] in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTINUUM Audio provides Self-Assessment CME credit when used as follows: When at least 8.0 CME credits have been earned and at least 25 posttest questions answered, those 8.0 CME credits count as Self-Assessment CME. Thereafter, all other credits earned continuously count as Self-Assessment CME. Audio Digest will report earned Self-Assessment credit on your behalf directly to the American Board of Psychiatry and Neurology (ABPN).
CONTINUUM Audio was co-developed by the American Academy of Neurology and Audio Digest and was planned to achieve scientific integrity, objectivity and balance. This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the University of Calgary Office of Continuing Medical Education and Professional Development.
Canadian participants can claim a maximum of 0 hours for this activity (credits are automatically calculated). See post-test instructions for further details. Note: Only CONTINUUM Audio courses published after May 31, 2018 are designated as Self-Assessment.

Audio Digest Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation. This activity provides 0.00 Rx contact hours.

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation. Lippincott Professional Development designates this activity for up to 0.00 CE contact hours.

Audio Digest Foundation is accredited by the American Association of Nurse Practitioners (AANP) as an approved provider of nurse practitioner continuing education, Provider number 030904.

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities designated for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Audio Digest lecture courses are individually designated for CME/CE credit; refer to individual program materials for specifics on credit designation.

Lecture ID:

ON120601

Qualifies for:

Expiration:

This CME course qualifies for AMA PRA Category 1 Credits™ for 35 months from the date of publication.

Instructions:

To earn CME/CE credit for this course, you must complete all the following components in the order recommended: (1) Review introductory course content, including Educational Objectives and Faculty/Planner Disclosures; (2) Listen to the audio program and review accompanying learning materials; (3) Complete posttest (only after completing Step 2) and earn a passing score of at least 80%. Taking the course Pretest and completing the Evaluation Survey are strongly recommended (but not mandatory) components of completing this CME/CE course. Canadian physicians utilizing this course for Self-Assessment (Section 3), as defined by the RCPSC, should refer to the provided Reflective Tool and visit MAINPORT to record your learning and outcomes.

Instructions:

To earn CME/CE credit for this course, you must complete all the following components in the order recommended: (1) Review introductory course content, including Educational Objectives and Faculty/Planner Disclosures; (2) Listen to the audio program and review accompanying learning materials; (3) Complete posttest (only after completing Step 2) and earn a passing score of at least 80%. Taking the course Pretest and completing the Evaluation Survey are strongly recommended (but not mandatory) components of completing this CME/CE course.

Estimated time to complete this CME/CE course:

Approximately 2x the length of the recorded lecture to account for time spent studying accompanying learning materials and completing tests.

More Details - Certification & Accreditation
No Pre Test defined for this Lecture

Pretest

Please complete this Pretest before listening to the audio program or reviewing the Written Summary. You may take the Pretest only once.
You have answered out of questions correctly. Your pretest score has been recorded. Scroll down to review your results.
Our records indicate that you have previously completed this pre-test (%). Your results have been recorded to your transcript.
loading... Loading...

Speakers

Jennifer R. Green, MD, Assistant Professor of Medicine, Deptartment of Medicine, Vanderbilt School of Medicine, Nashville, TN

Summary

Patient at risk: some variables are considered from different bleeding assessment scores; these patients can predispose to bleeding on anticoagulation; the challenge in listing multiple variables is assessment becomes clinically cumbersome and difficult to use; when using bleeding assessment score, ensure the patient matches the bleeding risk assessment score used (eg, do not use score for patient with venous thromboembolism when assessing patient with acute atrial fibrillation)

Anemia: it is observed in people who have already exhibited bleeding and tend to rebleed; if there is an anatomic abnormality identified, microscopic bleeding could be converted into macroscopic bleeding, with the addition of a blood thinner

Risks for bleeding: malignancy, hypertension, and a history of bleeding were identified at the American Society of Hematology’s 2019 annual meeting as risks for bleeding with the re-initiation of anticoagulation after an interruption for perioperative patients on direct oral anticoagulants (DOACs); hypertension continues to emerge throughout the literature as a modifiable risk factor for hemorrhagic and ischemic cerebrovascular accidents

Chronic kidney and hepatic disease: appear through many bleeding risk assessment scores, and are relevant to patients with congenital bleeding disorders

Assessment of benefit and risk: it is important to note that assessment of benefit and risk changes over time; risk for patients with, eg, an intracranial hemorrhage and who cannot be anticoagulated may change in 2 wk when hemostasis has been achieved; thus reassessment provides an opportunity to rebalance the risks and benefits in individual patients

An algorithmic approach to minimizing bleeding risk: includes the choice of whether to change the decision about anticoagulation, the duration of anticoagulation, the safest choice of the drug, and the monitoring needed throughout their anticoagulation duration to make it a highly safe treatment approach

Inferior vena cava (IVC) filters: these filters are valuable; they are indicated in a patient who cannot be anticoagulated and has typically a lower extremity deep vein thrombosis (DVT) that is high risk, and has an, eg, intracranial hemorrhage, very large gastrointestinal (GI) bleed; the American Society of Clinical Oncology (ASCO) recommended against its use in a chronic thrombosis setting in a venous thromboembolism (VTE) that is >4 wk old, and for temporary interruption; only retrievable filters should be used and they should be taken out as soon as the patient gets back on an anticoagulant

Duration of anticoagulation: for provoked VTEs, the patient is anticoagulated for 3 mo in the absence of an ongoing risk factor; conversely, for unprovoked VTEs, a decision needs to be taken at 3 mo as to whether the benefit of long-term anticoagulation is outweighed by the risk of bleeding; thoughtful reassessment is very crucial

VTE bleed: is a 6-variable score that is used to estimate risks for major bleeding during long-term anticoagulation; high-risk patients identified in data set had a 4-fold increased risk for bleeding; this score has been validated in the direct thrombin inhibitors, vitamin K antagonists, and factor 10a inhibitors for edoxaban and rivaroxaban as a useful score; further validation is warranted in a prospective real-world cohort; besides, this score is weighted toward 2 points for active cancer defined as a diagnosis or treatment for active malignancy in the past 6 mo

DOACs and strategies to minimize risks: chronic renal or hepatic dysfunction increases risk when using DOACs; apixaban and rivaroxaban, in particular, are metabolized by the liver and excreted by the kidney; ≈67% of rivaroxaban and 27% of apixaban are excreted renally; apixaban is authorized for use in end-stage renal disease with dialysis (2.5-mg dosing preferred vs 5-mg dosing; needs additional study)

Chronic pain and the use of nonsteroidal anti-inflammatory drugs (NSAIDs): can be very challenging for some patients with chronic arthritis when they are given an anticoagulant and are told they must discontinue their chronic NSAIDs; alternative opportunities for the patients include neuropathic pain management, Tai chi, or sometimes narcotics; alcohol abuse or use can cause thrombocytopenia, and cirrhosis has its physiologic predisposition to bleeding and clotting

Body mass index: some concerns were raised about using the DOACs in patients weighing >120 kg; warfarin sometimes used for patients who weigh >120 kg; however, some significant drug-drug interaction that occurs with the DOACs and human immunodeficiency virus medicines might impact the clinical practice; besides, an increased risk for GI bleeding might occur with DOACs in those with anatomic abnormalities of the gut

Laboratory monitoring of DOACs: in 2018, the Joint Commission issued a National Patient Safety Goal regarding monitoring; this has been interpreted as every 6 mo renal and hepatic function monitoring is required for patients who have normal creatinine clearance and every 3 mo for those who have a borderline creatinine clearance

Warfarin: hypertension is a significant modifiable risk factor as the central nervous system (CNS) bleeding rate is slightly higher with warfarin than with DOACs; centralized anticoagulation monitoring services have good outcomes; avoid excess alcohol and consider opportunities for tissue repair; the commonly used selective serotonin reuptake inhibitors (SSRIs) have antiplatelet activity that does not cause clinical bleeding, but can lead to some mucosal bruising and epistaxis in patients with other risk factors (eg, bleeding disorders, use of anticoagulants)

Mitigation of risk for patients with cancer: the ASCO guidelines were recently updated to include edoxaban and rivaroxaban as treatments for VTE, but apixaban and dabigatran were excluded because of limited published data; an increased risk for GI bleeding in GI malignancies was observed in DOACs cases, and this was across all subsets of GI malignancies; rivaroxaban has been used in patients with primary CNS malignancies who develop an acute symptomatic DVT; a recent study showed that patients taking DOACs had no intracranial hemorrhage within 12 mo; it is considered DOACs might be safer than low molecular weight heparin in patients with primary CNS tumor; ASCO recommends that anticoagulation should be offered to patients who have primary CNS malignancy and an established VTE

Bariatric surgery: can influence drug levels; reduced caloric intake can affect bioavailability; rivaroxaban needs concurrent food administration for optimal bioavailability; decreased surface area for absorption and alkaline pH could impact medications (eg, dabigatran); location of drug absorption can possibly predict the effect on their pKa values; apixaban may primarily undergo gastric absorption in the small intestine, and a small amount possibly in the ascending colon; for dabigatran, the lower stomach and duodenum; for edoxaban, it is predominantly proximal small intestine; warfarin is proximal small intestine; vitamin K antagonist is preferred in patients who have had bariatric surgery; diluted thrombin time helps to decide whether bleeding patients should receive a hemostatic reversal agent or whether they need surgery; ecarin clotting time, ecarin chromogenic assay, and anti-factor Xa assay are used to measure therapeutic drug levels to determine if on-therapy or above-therapy levels are present

Readings

Balabhadra S et al. Association of inferior vena cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis. JAMA Netw Open. 2020;3:e2011079. Published 2020 Jul 1. doi:10.1001/jamanetworkopen.2020.11079; Buchwald H et al. Bariatric surgery: a systematic review and meta-analysis [published correction appears in JAMA. 2005 Apr 13;293(14):1728]. JAMA. 2004;292:1724-1737. doi:10.1001/jama.292.14.1724; de Oliveira Manoel AL et al. The critical care management of spontaneous intracranial hemorrhage: a contemporary review. Crit Care. 2016;20:272; doi:10.1186/s13054-016-1432-0; Lake MB et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000;10:35-38; doi:10.1089/cap.2000.10.35; Silczuk A et al. Thrombocytopenia in patients hospitalized for alcohol withdrawal syndrome and its associations to clinical complications. Alcohol Alcohol. 2019;54:503-509; doi:10.1093/alcalc/agz061; Wang X et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636; doi:10.1002/jcph.628.

 
No Post Test defined for this Lecture
Posttest

This posttest is locked because you have non-CME access only.

This Posttest was previously completed as part of:

Volume , Issue : / NaN/NaN/NaN

Visit CD Testing to view the completed test associated with this lecture.

Posttest

Posttest.

You should complete this Posttest only after listening to the audio program and reviewing the Written Summary. You may retake this test as many times as necessary to earn a passing score.
You should complete this Posttest only after listening to the audio program and reviewing the Written Summary. You may take the Postest only once and must earn a score of ≥80% to pass. At the end of the Posttest, you are required to complete the Evaluation in order to earn Class A CE Credit for this activity.
Congratulations! You have passed!
Score= % ( out of questions correctly)
Credits =
To complete this activity, please proceed to the Evaluation tab.
Canadian participants: Please also complete the provided Reflective Tool and visit MAINPORT (mainport.org/mainport) to record your learning and outcomes.
Congratulations! You have passed your first posttest. Upgrade here to access more posttests.
Score= % ( out of questions correctly)
Credits =
To complete this activity, please proceed to the Evaluation tab.
Canadian participants: Please also complete the provided Reflective Tool and visit MAINPORT (mainport.org/mainport) to record your learning and outcomes.
To complete this activity, please proceed to the Evaluation tab.
Congratulations! You have passed!
Score= % ( out of questions correctly)
Credits =
Our records indicate that you have previously completed this post-test (%). You are eligible to claim credit for this activity and your results have been recorded to your transcript.
You have not achieved a passing score of ≥80%, and may not retest. You are unable to earn Class A CE Credit for this activity. You have not passed the test.
Score = % ( out of questions answered correctly)
loading... Loading... {"Message":"Authorization has been denied for this request."}
loading... Loading... {"Message":"Authorization has been denied for this request."}
Congratulations! You have passed! Score= % ( out of questions correctly)
Credits =
You have not passed the test. Score = % ( out of questions answered correctly)
See your answers
×


Canadian participants: A Reflective Tool for this activity is available to print out and complete by hand. This is for your personal use. To access the Reflective Tool, please
CLICK HERE.

Learner Assessment and Program Evaluation --

Guest

AANA ID:

Learner Assessment and Program Evaluation --

Your responses to this Evaluation Survey are important. The more complete your answers, the more we can accurately assess (1) how well this program has met your educational needs, and (2) how we can continue to provide content that matches the scope of your practice. This Evaluation Survey must be completed in full* and submitted along with a completed test (passing grade of ≥80%) in order to receive credit for this activity.
  • THANK YOU FOR YOUR PARTICIPATION!

  • Audio Digest may display ratings and comments (anonymously) on its website and in other communications.


ADF loader Loading...


×